Sograzepide

Overview

Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active Gastrin/CCK-B antagonist with an IC 50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC 50 of 502 nM. Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with K i values of 0.068, 0.62 and 0.19 nM, respectively.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Metabolic Disease | Products > Research Areas > Endocrinology | Products > Signaling Pathways > Cholecystokinin Receptor

Product Information

• Catalog No.: HY-14850
• CAS No.: 155488-25-8
• Molecular Formula: C28H30N6O3
• Molecular Weight: 498.58
• Purity: 98.04%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (4.17 mM); Clear solution
• Availability: In-stock

Source

Original product source